One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach? Medical experts weigh in.

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

RDX-002, a novel iMTP inhibitor, showed promising results in a Ph2 study, reducing blood fat and weight regain after GLP-1 ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern ...

The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

GLP-1 agonists are medications that primarily treat type 2 diabetes and obesity. However, recent studies suggest they can lower blood pressure, reduce inflammation and improve lipid disorders.